These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
821 related articles for article (PubMed ID: 16750621)
21. The thalidomide saga. Melchert M; List A Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076 [TBL] [Abstract][Full Text] [Related]
22. Lenalidomide for the treatment of B-cell malignancies. Chanan-Khan AA; Cheson BD J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605 [TBL] [Abstract][Full Text] [Related]
23. Thalidomid: current role in the treatment of non-plasma cell malignancies. Kumar S; Witzig TE; Rajkumar SV J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211 [TBL] [Abstract][Full Text] [Related]
24. Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. Tariman JD Clin J Oncol Nurs; 2007 Aug; 11(4):569-74. PubMed ID: 17723971 [TBL] [Abstract][Full Text] [Related]
25. Current status of new drugs for the treatment of patients with multiple myeloma. Kenealy M; Prince HM Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741 [TBL] [Abstract][Full Text] [Related]
26. IMiDs: a novel class of immunomodulators. Knight R Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014 [TBL] [Abstract][Full Text] [Related]
28. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. Maier SK; Hammond JM Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of lenalidomide in multiple myeloma. Schey S; Higginson I Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):229-38. PubMed ID: 20545587 [TBL] [Abstract][Full Text] [Related]
30. Thalidomide in the treatment of multiple myeloma. Kastritis E; Dimopoulos MA Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713 [TBL] [Abstract][Full Text] [Related]
34. Thalidomide: from teratogen to anti-angiogenic. Grover JK; Vats K Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882 [TBL] [Abstract][Full Text] [Related]
35. The potential of immunomodulatory drugs in the treatment of solid tumors. Dalgleish A; Galustian C Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830 [TBL] [Abstract][Full Text] [Related]
36. Lenalidomide in multiple myeloma: Current status and future potential. Quach H; Kalff A; Spencer A Am J Hematol; 2012 Dec; 87(12):1089-95. PubMed ID: 22641420 [TBL] [Abstract][Full Text] [Related]
37. Lenalidomide in multiple myeloma: current experimental and clinical data. Cives M; Milano A; Dammacco F; Silvestris F Eur J Haematol; 2012 Apr; 88(4):279-91. PubMed ID: 22085323 [TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma. Suppiah R; Srkalovic JG; Hussein MA Clin Lymphoma Myeloma; 2006 Jan; 6(4):301-5. PubMed ID: 16507207 [TBL] [Abstract][Full Text] [Related]